Diagnostic Medical Systems

Earnings Release • Apr 20, 2023

April 20, 2023 – 6:00 p.m.

Record quarterly revenue: €10.1 million in the 1st quarter of 2023, organic growth +16%

• Radiology: 6% growth in 1st quarter /+22% in the United States First deliveries of record order from Fujifilm Healthcare Italy will begin 2 nd quarter
• Bone densitometry: strong quarterly growth: +69%

Confirmation of 2023 targets and perspectives

• €40 million in revenue, i.e., double-digit organic growth
• Expected increase in EBITDA margin

Diagnostic Medical Systems Group (Euronext Growth Paris - FR0012202497 - ALDMS) French medical imaging specialist, announces its consolidated revenue for the 1 st quarter of 2023 (period from January 1 to March 31, 2023). Following the divestment of 17.00% of Hybrigenics' capital in February 2023¹ , the DMS Group currently retains a 24.77% stake in the capital. As of January 1, 2023 Hybrigenics is no longer consolidated in the DMS Group accounts.

Unaudited consolidated data in M€ IFRS standards	st quarter 1 2023	st quarter 1 2022	Variation
Revenue	10.1	8.72	+16%
Radiology activity	7.7	7.3	+6%
Bone densitometry activity	2.4	1.4	+69%

The DMS Group generated consolidated revenue of €10.1 million in the 1 st quarter 2023 representing +16% of organic growth² and marking the largest quarterly revenue ever earned in a 1 st quarter.

Review by activity

In Radiology, revenue amounted to €7.7 million, a quarterly growth of +6%. 1 st quarter activity did not include any deliveries of the 96 FDX Visionary-RF Premium remote-controlled radiology tables won in a tender by Fujifilm Healthcare Italy³ . The first deliveries for this order will begin in the 2 nd quarter of 2023 and will ramp up throughout the year.

The Radiology business continued its strong development in the United States at the start of the exercise, with +22% growth in the region, driven by distribution agreements with Fujifilm Healthcare and Carestream Health. The DMS Group manufactures white-label remote-controlled radiology tables offered by:

• Fujifilm Healthcare in Europe, Africa, Middle East, and North America.
• Canon Medical Systems Europe in the Europe area.
• Carestream Health in North and South America.

3Read press release of January 12, 2023

¹Read press release of February 8, 2023.

²Revenue for the 1st quarter of 2023 does not include revenue from Hybrigenics, which has been deconsolidated since January 1, 2023. As a reminder, Hybrigenics had generated revenue of €0.2 million in the 1st quarter 2022.

DMS Group also markets its solutions under its own brand, Apelem, to a network of 140 distributors around the world.

In Bone densitometry, the Group registered a strong 1 st quarter 2023, recording +69% growth. This performance reflects the success of our distribution agreement with Fujifilm Healthcare as well as an acceleration in sales in Europe and Asia, where sales activities had begun to resume at the end of 2022.

Confirmation of 2023 revenue target: €40 million

At the end of an historic 1 st quarter, the Group remains confident in its objective of €40 million consolidated annual revenue. The Radiology activity will begin deliveries of the 96 tables to Fujifilm Healthcare Italy over the next few quarters, and sustained activity in both radiology and bone densitometry will allow the Group to reach double-digit organic growth compared to 2022.

The Group also confirms the improvement in its profitability in 2023, with an expected improvement in its EBITDA margin⁴ .

As set forth in the Imaging 2027 plan, the DMS Group has fixed the objectives of registering €60 million revenue and an EBITDA margin of 14% in 2027.

Date	Event
April 28, 2023	Publication of 2022 annual results
July 20, 2023	Publication of 2023 half-year revenue
September 29, 2023	Publication of 2023 half-year results
October 19, 2023	rd quarter revenue Publication of 2023 3
January 18, 2024	Publication of 2023 annual revenue
April 30, 2024	Publication of 2023 annual results

Financial calendar 2023

The publications will be made after Euronext Paris market closing. These dates are given as an indication, they may be changed if necessary.

About DMS Group

The DMS Group is a French leader in the development, design and manufacturing of imaging systems dedicated to radiology, and bone densitometry.

The DMS Group is present on all continents through a network of more than 140 national distributors, subsidiaries, and joint ventures.

DMS Group is listed on the Euronext Growth market in Paris (ISIN: FR0012202497 - mnemo: ALDMS).

More information at www.dms.com.

RECEIVE ALL DMS GROUP FINANCIAL INFORMATION FREE BY EMAIL BY SUBSCRIBING ON WWW.ACTUSNEWS.COM . contacts

CEO	+33 (0)4 67 50 49 00
Investor Relations	+33 (0)1 53 67 36 92
Press Relations	+33 (0)1 53 67 36 34

⁴EBITDA corresponds to the recurring operating income before interest, taxes, depreciations, and amortization.